TOP 1630

Drug Profile

TOP 1630

Alternative Names: TOP1630

Latest Information Update: 29 Nov 2016

Price : $50

At a glance

  • Originator TopiVert
  • Class
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors; Protein kinase inhibitors; Src-Family kinase inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Dry eyes

Highest Development Phases

  • Preclinical Dry eyes

Most Recent Events

  • 28 Nov 2016 US FDA approves IND application for TOP 1630 in Dry eye
  • 16 May 2016 TopiVert completes Preclinical trials in Dry eyes
  • 11 Mar 2016 TOP 1630 is available for licensing as of 11 Mar 2016. http://www.topivert.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top